Agendia B.V.

Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting

    Huntington Beach, California and Amsterdam, June 4, 2010 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test. FDA clearance requires clinical and analytical validation and full transparency to ensure patient safety issues are addressed. The company anticipates launching its prognostic colon cancer test ColoPrint in late 2010.

    The study results underpin the broad predictive and prognostic power of MammaPrint and highlight prospective and independently validated data on ColoPrint. Visitors can meet the Agendia team in booth #18018 and study results will be discussed at the following sessions:

@@start.t1@@      Breast Cancer
      Date: Saturday, June 5, 2010
      POSTER PRESENTATION - Abstract #10615
      Substratification of 70-gene high-risk breast cancers with a
      validated 80-gene molecular subtyping profile
      F. de Snoo, B. Chan, P. Roepman, R. A. Bender, A. Glas
      Time: 8:00 AM - 12:00 PM
      Location: S Hall A2
      Date: Saturday, June 5, 2010
      POSTER PRESENTATION - Abstract # 540
      Gene signatures as predictors of response to neoadjuvant
      chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC),
      or AC and nab-paclitaxel (nab-P) and carboplatin plus or minus
      trastuzumab in patients (pts) with stage II-III and inflammatory breast
      cancer (IBC)
      G. Somlo, P. H. Frankel, L. Vora, S. Lau, T. H. Luu, L.
      Kruper, J. Yim, Y. Yen, F. de Snoo, R. A. Bender
      Time: 2:00 PM - 6:00 PM
      Location: S Hall A2
      Date: Saturday, June 5, 2010
      POSTER PRESENTATION - Abstract # 561
      Evaluation of the 70-gene prognosis MammaPrint signature for
      the prediction of prognosis of breast cancer independently from
      histologic grade
      M. Knauer, E. J. Rutgers, S. Mook, J. Wesseling, L. J. van 't
      Veer
      Time: 2:00 PM - 6:00 PM
      Location: S Hall A2
      Date: Monday, June 7, 2010
      POSTER DISCUSSION - Abstract # 1520
      Effect of screening on the detection of good and poor
      prognosis breast cancers
      Y. Shieh, L. Esserman, E. J. Rutgers, M. Knauer, V. Retel, S.
      Mook, A. Glas, S. C. Linn, F. E. van Leeuwen, L. van't Veer
      Time: 2:00 PM - 6:00 PM / 5:00 PM - 6:00 PM (discussion in
      E451b)
      Location: E450b
      Colon Cancer
      Date: Monday, June 7, 2010
      POSTER PRESENTATION - Abstract # TPS199
      The PARSC trial, a prospective study for the assessment of
      recurrence risk in stage II colon cancer (CC) patients using ColoPrint
      R. Salazar, J. Marshall, L. Stork-Sloots, I. Simon, M. Lutke
      Holzik, J. Tabernero, J. J. Van Der Hoeven, F. Bibeau, R. Rosenberg
      Time: 8:00 AM - 12:00 PM
      Location: S Hall A2
      Date: Tuesday, June 8, 2010
      POSTER DISCUSSION - Abstract # 3513
      Independent validation of a prognostic genomic profile (ColoPrint) for
      stage II colon cancer (CC) patients
      R. Rosenberg, M. Maak, U. Nitsche, T. Schuster, B. Kuenzli, M. Snel, I.
      Simon, K. Janssen, H. Friess
      Time: 11:00 AM - 12:00 PM
      Location: S 406 (Vista Room)@@end@@

    About MammaPrint(R)  

    MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis risk - patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

    All MammaPrint tests are conducted in Agendia's CAP-accredited and CLIA compliant service laboratories.

    About Agendia  

    Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
CONTACT:  MEDIA CONTACTS: Hans Herklots, Agendia, +31-20-462-1557
Office,+31-620-083-509 Mobile, hans.herklots@agendia.com; Valerie
Delva, RicochetPublic Relations, +1-212-679-3300 x128 Office,
+1-917-755-6194 Mobile,vdelva@ricochetpr.com



Weitere Meldungen: Agendia B.V.

Das könnte Sie auch interessieren: